AURA - CIK 0001501796
The table below shows Aura Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $90.30M | $73.30M | $65.23M | $42.24M | $25.16M | $18.04M |
| SG&A | $22.49M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $22.81M |
| $19.76M |
| $18.06M |
| $10.09M |
| $4.16M |
| Operating income | -$112.79M | -$96.12M | -$84.99M | -$60.30M | -$35.25M | -$22.21M |
| Income tax | $108.00K | $112.00K | $137.00K | $0.00 | $0.00 | $0.00 |
| Net income | -$106.19M | -$86.92M | -$76.41M | -$58.76M | -$35.25M | -$22.21M |
| EPS (diluted) | -$1.76 | -$1.75 | -$1.93 | -$1.96 | -$8.95 | - |